



**BOLT**  
BIOTHERAPEUTICS

**Bolt Biotherapeutics**  
Nasdaq: BOLT

**Boltbody™ ISAC Platform**

October 2023

# Disclaimer

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding Bolt Biotherapeutics, Inc. (the "Company," "we," "us," or "our")'s future financial condition, ability to achieve upcoming milestones for our product candidates, the timing of our clinical trials, and the success and results of our pipeline programs and partnerships, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "should," "will" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the success, cost and timing of our product development activities and clinical trials; our expectations about the timing of achieving regulatory approval and the cost of our development programs; our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates; our ability to fund our clinical programs and the sufficiency of our cash, cash equivalents, and marketable securities to fund operations through 2025 and the achievement of key milestones; the commercialization of our product candidates, if approved; our plans to research, develop, and commercialize our product candidates; our ability to attract collaborators with development, regulatory and commercialization expertise; future agreements with third parties in connection with the commercialization of our product candidates; the success of our current collaborations with third parties, including our collaborations with Bristol-Myers Squibb Company, Roche, Innovent Biologics, Inc., Genmab A/S, and Toray Industries, Inc.; the achievement of milestone payments or any tiered royalties related to our collaborations; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; the rate and degree of market acceptance of our product candidates; and regulatory developments in the United States and foreign countries. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K for the year ended December 31, 2022. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

# Bolt Bio: Dedicated to Generating Breakthroughs for Patients

## BDC-1001: Monotherapy Activity, Efficient Plan

### Promising Phase 1 Results

- Monotherapy ORR<sup>1</sup> of 29% at RP2D of 20 mg/kg q2w
- Well tolerated

### Phase 2 Program

- Option-based development
- 4 tumor types
- Upcoming data readouts

## Focused Pipeline, Proven Platform Technology

### Pipeline

- BDC-1001 in Phase 2
- BDC-3042 in Phase 1

Collaborations validate Boltbody™ ISAC platform



## Well-Capitalized, Significant Upside Potential

### Nasdaq: BOLT

- 6 covering research analysts
- Consensus price target: \$5.00<sup>2</sup>

\$157M cash & equivalents<sup>3</sup>

### Simple Corporate Structure

- 37.95 million shares of common stock outstanding<sup>4</sup>
- No debt
- No warrants

<sup>1</sup> Objective Response Rate in evaluable patients with HER2+ tumors

<sup>2</sup> \$5.00 is consensus price target of 6 covering analysts as of 8/31/23

<sup>3</sup> \$157.1 million cash & cash equivalents

<sup>4</sup> 37,950,986 shares outstanding as of 6/30/23

RP2D = Recommended Phase 2 Dose

q2w = every other week dosing schedule

ISAC = Immune-Stimulating Antibody Conjugate




**BOLT**  
BIOTHERAPEUTICS

## Boltbody™ ISAC Platform

# Boltbody™ ISAC Platform

Best-in-class ISAC Platform with Emerging Clinical Validation



## Proven Ability to Achieve:

- ✓ Target-dependent activity
- ✓ Low systemic cytokine production
- ✓ Low immunogenicity

### Antibody

- Targets tumor antigen
- Active Fc essential for phagocytosis
- Impacts ISAC PK, activity & safety

### Payload

- 100s of payloads evaluated
- TLR7, TLR8, dual TLR7/8 & STING payloads available

### Linker

- Non-cleavable for better safety
- Optimize physicochemical properties

### Conjugation


- Suite of modern & classical methods available
- Conjugation site impacts activity & safety

# Innate Immune Response

Myeloid Cells Kill Tumor Cells via ADCP

## TUMOR MICROENVIRONMENT


1 Tumor Antigen Recognition



### Antigen Expression

- High, medium, & low


2 FcR-Dependent Phagocytosis (ADCP)



### Myeloid Antigen-presenting Cells

- Monocytes
- Macrophages
- pDCs and cDCs

3 TLR-Mediated Activation



### Activated Myeloid Cells

- Chemokine & cytokine secretion
- Enhanced antigen presentation

# Adaptive Immune Response

Engages T Cell-driven Tumor Killing

## TUMOR-DRAINING LYMPH NODES

4


T cell Priming & Expansion



## TUMOR MICROENVIRONMENT




5

T Cell Killing of Tumor Cells



### Result: An Immune "Hot" Tumor


- Chemokines attract immune effector cells
- Cytokines lower immune activation threshold
- Increases myeloid APC phagocytosis
- Activated T cells migrate to tumor



# ISACs Deliver Powerful Synergies

## Covalent Attachment of TLR7/8 Agonist Dramatically Improves Anti-tumor Efficacy


### HCC1954 Tumor Xenograft Model



- SCID/Beige lack T, B and functional NK cells, but retain a myeloid compartment
- Enables assessment of myeloid-mediated anti-tumor activity


Adapted from Creative Biolabs

### Single ISAC Dose Mediates Tumor Regression




# Preclinical Boltbody™ ISAC Data Shows Advantage to Combining TLR7 and TLR8

## TLR7/8 Dual Agonist Provides an Amplification of Immune Response




## TLR7/8 Dual Agonist Results in Enhanced Myeloid Activation

### TLR7/8 ISAC vs. TLR8 ISAC (CD86)



### TLR7/8 ISAC vs. TLR7 ISAC (CD86)






# Boltbody™ ISAC Induces Immune Memory that Extends to Tumors Lacking HER2


## Immunity Extends to Tumor Neoantigens through Epitope Spreading

### Heterogenous HER2+ Tumors 10% of Tumor Cells Lack HER2 Expression


#### In Vivo rHER2 Expression



### Epitope Spreading with ISAC Clearance of Heterogenous Tumors in Mice



### Rechallenge with HER2<sup>neg</sup> CT26 Epitope Spreading Dependent on T Cells



## CT26-rHER2+ or CT26-rHER2<sup>neg</sup> Syngeneic Colorectal Cancer Models

# Strategic Collaborations Provide External Validation for Boltbody™ Platform

## Innovent

Fully integrated biopharma with large antibody library and strong presence in Greater China

- Innovent funds up to 3 Boltbody™ ISACs through early clinical development
- Bolt has option to co-develop & commercialize 2 candidates in certain regions
  - Bolt received \$5M upfront; eligible for future milestones & royalties

## Genmab

Innovative leader in antibody & bispecific development for oncology

- Genmab funds 3 bispecific Boltbody ISACs through early clinical development
- Bolt has option to co-develop & commercialize 1 candidate in certain regions
  - Bolt received \$25M upfront; eligible for up to \$285M in milestones plus tiered royalties per program exclusively developed & commercialized by Genmab

## TORAY

Global leader in innovative technologies, conducting research in cancer immunotherapeutics

- Toray funds Boltbody ISAC for specific & novel target through end of Phase 1
- Global co-development/co-commercialization



**BOLT**  
BIOTHERAPEUTICS

Thank You